NasdaqGM:TVTXBiotechs
Travere Therapeutics (TVTX) Is Up 6.1% After FILSPARI Beats FSGS Launch Expectations
Travere Therapeutics recently reported that FILSPARI’s launch in FSGS is outperforming expectations with broad physician demand across a U.S. pool of more than 30,000 biopsy-confirmed patients.
The company is also pushing its rare disease pipeline forward with a Phase III trial of pegtibatinase in classical homocystinuria and adding civorebrutinib for multiple renal indications affecting roughly 130,000 patients, underscoring a widening kidney-focused franchise.
We’ll now examine how...